Soraya Bekkali, MD

Soraya Bekkali, MD has a long and varied work experience in the pharmaceutical industry. Soraya began their career in 2003 as an Associate Medical Director at Orphan Europe. In 2007, they joined sanofi-aventis as a Clinical Research Director, where they were the global clinical leader of a late stage drug development program in a rare cardiovascular indication. In 2009, they moved to Sanofi as Global Ophthalmology Business Unit Head, where they were responsible for the overall global strategy, business development, commercial and R&D operations. Soraya also led the company towards investing in ocular gene therapy. In 2016, they joined LYSOGENE as SVP Chief Medical Officer. In 2017, they became Chief Executive Officer at GYROSCOPE Therapeutics Ltd. In 2020, they were appointed Chief Executive Officer at Cellinta Limited. In 2021, they joined Alexion Pharmaceuticals, Inc. as SVP Commercial International and Vedere Bio II as Non Executive Director, where they are responsible for developing next-generation ocular gene therapies for vision restoration and preservation in patients with vision loss due to photoreceptor death.

Soraya Bekkali, MD obtained their Medical Degree from Université Paris Cité between 1990 and 2000.